$GH

Tariq Musa sold $256K of GH

Tariq Musa sold 1,951 shares of Guardant Health, Inc. (GH) at $131.16 ($0.26M total) on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tariq Musa
Published Jun 23, 2026, 9:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 23, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
high confidence
Mentioned
$GH
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

A director’s pre-arranged open-market sale is typically not a fundamental catalyst; it may slightly influence sentiment but rarely drives price on its own.

02

Market read

Traders may log the sale for insider-trading monitoring, but it is unlikely to change the near-term fundamental outlook.

03

What to watch

The filing does not reveal intent beyond the pre-arranged plan; without additional insider buys/sales context, signal-to-noise is low.

Relevance 3/10Novelty 3/10Timing: after-hours/filing date (2026-06-23) for a 2026-06-22 sale

Background

The article is a SEC Form 4 insider transaction disclosure for Guardant Health, Inc.

Company-level read

Ticker impact

$GHNeutralHigh confidence
Context

Guardant Health director Tariq Musa filed a Form 4 showing an open-market sale of 1,951 shares at $131.16 on 2026-06-22 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this filing.

Evidence & confidence

The disclosure is a pre-arranged 10b5-1 open-market sale by a director; it does not indicate new fundamentals, guidance, or regulatory/operational events.

Market effects

Minimal; this is company-specific insider transaction data with no stated sector catalyst.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with private views on valuation; traders may still watch for follow-on insider selling clusters.

Key entities

  • Guardant Health, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Tariq Musa

    Director who sold 1,951 shares under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHMed

Guardant Health stock hits 52-week high at 176.68 USD

Guardant Health Inc. (GH) hit a 52-week high of $176.68, up 216.17% in a year. Q2 revenue grew 44% to $335M, beating expectations. Analysts raised price targets, with Stifel at $180 and TD Cowen at $210, both maintaining Buy ratings. Positive outlook driven by healthcare advancements and strong product performance.

$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.

$GHHighAI 9/10

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH in advanced breast cancer. The approval, based on the SERENA-6 trial, showed a 56% reduction in disease progression risk when using ctDNA-guided treatment. The test is recommended for use every three months during therapy.

$GHHighAI 9/10

Final judgement favours TwinStrand in Guardant patent case

TwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.